Changmao Biochemical Engineering Company Limited (00954) released its monthly return for January 2026 and reported no changes to the company’s authorized or issued share capital. The authorized share capital remains RMB52,970,000, composed of 183,700,000 H shares, 2,500,000 domestic shares, and 343,500,000 foreign shares, each at a par value of RMB0.1.

According to the return, the number of issued H shares remains at 183,700,000, while domestic shares and foreign shares stand at 2,500,000 and 343,500,000 respectively. There are no treasury shares, and the minimum public float threshold of 25% of total issued shares is confirmed to have been met.

No new share options, warrants, convertible securities, or any other arrangements to issue shares are reported. The report concludes with confirmations from the company secretary that all relevant listing and regulatory requirements have been duly satisfied.